MedTrace Logo

Results of an Interferon-Gamma Release Assay After Treatment for Tuberculosis

NCT00595907 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 89

Last updated 2008-01-16

No results posted yet for this study

Summary

New blood tests have become available to detect either latent or active tuberculosis. These tests - which according to the CDC can replace the tuberculin skin test - measure the production of gamma-interferon (a cytokine) by peripheral lymphocytes (white cells) when exposed to antigens which are highly specific of mycobacterium tuberculosis (the bacteria responsible for tuberculosis). Our hypothesis was that the production of gamma-interferon would be much higher at the beginning of treatment than at the end, and that decline in gamma-interferon secretion could be an indicator of clinical response to treatment.

Conditions

Sponsors & Collaborators

  • Ligue Pulmonaire Genevoise

    collaborator OTHER

  • University Hospital, Geneva

    lead OTHER

Principal Investigators

  • Jean-Paul Janssens, M.D. · University Hospital, Geneva

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2006-07-31
Completion
2006-07-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00595907 on ClinicalTrials.gov